Clinical Trial Detail

NCT ID NCT03277352
Title INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Biosciences International Sàrl
Indications

Advanced Solid Tumor

renal cell carcinoma

transitional cell carcinoma

melanoma

Therapies

Epacadostat + INCAGN01876 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.